European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

AbbVie Deutschland GmbH & Co. KG

Register

Ut
District Court of Wiesbaden HRA 9790
Lei
549300FI0P3XDOCBXJ78

Address

Mainzer Str. 81, 65189 Wiesbaden, Germany

Corporate purpose

Research and development, production and processing, and distribution of and trade of chemical, pharmaceutical, diagnostic and medical products as well as nutritional products. The Company is entitled to conduct all transactions which are likely to promote the business, including the establishment and operation of branches, and the acquisition and sale of immovable property and the ordering of liens.

Financials

Employees

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Marketing & Tech

Network

Loading network

JOBS AT NORTH DATA

  • Director, Engineering
  • Modern Java Developer

Publications

30 Apr 2024
No longer Officer (1)
26 Feb 2024
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022 · Shareholding: % der Anteile an der AbbVie Komplementär GmbH
9 Feb 2024
Officer (1) · Limited Partner: AbbVie Inc
21 Dec 2023
Officer (1)
4 Dec 2023
Officer (4) · No longer Officer (4)
22 Aug 2023
Officer (2)
6 Jul 2023
Officer (2) · No longer Officer (1)
24 May 2023
Officer (4) · No longer Officer (2)
21 Apr 2023
Officer (6) · No longer Officer (7)
13 Apr 2023
Officer (4) · No longer Officer (1)
1 Feb 2023
Officer: Anne-S. C. Dominici
27 Jan 2023
Officer (3) · No longer Officer (2)
7 Oct 2022
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021 · Shareholdings: % der Anteile an der AbbVie Komplementär GmbH, % der im Geschäftsjahr …
29 Sept 2022
Officer (1)
16 Sept 2022
Word figurative mark: “xellex xellex“
31 Aug 2022
Officer (1)
6 Jul 2022
Officer (4) · No longer Officer (1)
11 May 2022
Officer (4) · No longer Officer (3)
2 May 2022
Merger: Allergan GmbH
25 Apr 2022 via Allergan GmbH
Merger: Allergan GmbH
6 Apr 2022
Officer: Anne-S. C. Fritz · No longer Officer (2)
11 Mar 2022
Officer (2)
17 Feb 2022
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
6 Jan 2022
Patent: Methods of Treating Crohn's Disease and Ulcerative Colitis
3 Jan 2022
Officer (1) · No longer Officer (1)
Year 2021 in Epobase
5 European patent filings: Spiro-Cyclic Amine Derivatives AS S1P Modulators …
27 Oct 2021
No longer Officer (5) · Officer (1)
1 Oct 2021 in Fk
Public funding (€69,439): PROXIDRUGS: An Assay and Screening Platform for Molecular Degraders (ProxiDETECT) - B
1 Oct 2021 in Fk
Public funding (€59,665): PROXIDRUGS: Validation of molecular degraders in neuronal models (AntiDEG) - B
1 Oct 2021 in Fk
Public funding (€56,099): PROXIDRUGS: Overcoming Biological Barriers to Proxidrug Delivery (BioDEL) - D
12 Jul 2021
No longer Officer (1)
11 Jun 2021
Officer (2) · No longer Officer (1)
7 Apr 2021
Officer: Anne-S. C. Fritz, Jean-L. Gantmacher · No longer Officer (1)
9 Mar 2021
Officer (11) · No longer Officer (3)
25 Jan 2021
Officer: Andreas Rudolf Beck
24 Nov 2020
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
Year 2020 in Epobase
4 European patent filings: Dosing Regimens for USE in Treating Myelofibrosis and MPN-Related Disorders with Navitoclax …
20 Oct 2020
Officer (1)
16 Oct 2020
No longer Officer (1)
22 Jul 2020
Officer (1) · No longer Officer (1)
10 Jun 2020
Officer (2) · No longer Officer (1)
30 Apr 2020
No longer Officer (2)
10 Mar 2020
Officer (4)
10 Feb 2020
Officer (1)
27 Jan 2020
Officer (3) · No longer Officer (4)
11 Nov 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
8 Nov 2019
Officer (3) · No longer Officer (2)
9 Sept 2019
Officer (1) · No longer Officer (1)
4 Sept 2019
Patent: Anti-Amyloid Beta Antibody
27 Jun 2019
Officer (2)
17 May 2019
Officer (11) · No longer Officer (4)
Year 2019 in Epobase
7 European patent filings: Aminotetraline and Aminoindane Derivatives, Pharmaceutical Compositions Containing Them, and Their USE in Therapy …
1 Mar 2019
No longer Officer (3)
18 Feb 2019
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
1 Feb 2019
Officer (4) · No longer Officer (1)
Year 2018 in Epobase
16 European patent filings: Isoindoline Derivatives, Pharmaceutical Compositions Containing Them, and Their USE in Therapy …
30 Nov 2018
No longer Officer (1)
18 Oct 2018
Officer (1) · No longer Officer (1)
18 Sept 2018
Officer (1)
19 Jul 2018
No longer Officer (1)
19 Apr 2018
Officer (3) · No longer Officer (2)
24 Jan 2018
Patent: Pharmaceutical dosage form for oral administration of a BCL-2 family inhibitor
Year 2017 in Epobase
24 European patent filings: Method for Producing Ultrafine Submicronic Suspensions …
5 Dec 2017
Officer (6) · No longer Officer (6)
20 Nov 2017
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
Year 2017 in Euipods
6 registered designs
3 Aug 2017
Patent: Organic reactions in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkyl cellulose
19 Jul 2017
Officer (1)
26 May 2017
Patent: Nanoparticles based on Optional Alkoxylated Poly (Alkylcyanacrylates) with Defined Degree of Polymerization
12 Apr 2017
No longer Officer (2) · Officer (1)
9 Mar 2017
Officer (5) · No longer Officer (1)
1 Mar 2017 in Hor
EU funding: Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060
1 Jan 2017 in Hor
EU funding: Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106
1 Jan 2017 in Hor
EU funding: Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030
Year 2016 in Epobase
29 European patent filings: Heterocyclic Compounds and Their USE AS Glycogen Synthase Kinase-3 Inhibitors …
23 Dec 2016
No longer Officer (4) · Officer (1)
1 Nov 2016 in Hor
EU funding: Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976
1 Oct 2016 in Hor
EU funding: Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975
29 Sept 2016
No longer Officer (3) · Officer (2)
5 Sept 2016
Annual report for the year ending 31/12/2015 · Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015 · Shareholding: 100% der Anteile an der AbbVie Komplementär GmbH, die Komplementärin …
16 Jun 2016
Officer (3)
17 Mar 2016
Patent: 4.5-Dihydropyrazole Derivatives, Pharmaceutical Compositions With It and their Use in Therapy
3 Mar 2016
No longer Officer (2) · Officer (2)
10 Feb 2016
Patent: Pharmaceutical dosage form for oral administration of a BCL-2 family inhibitor
5 Jan 2016
No longer Officer (4)
9 Dec 2015
No longer Officer (2) · Officer (1)
Year 2015 in Epobase
14 European patent filings: Monoclonal Antibodies Against the RGM a Protein for USE in the Treatment of Retinal Nerve Fiber Layer Degeneration …
Year 2015 in Dp
4 patent filings: Hexahydrodiazepine quinine with A Substituted Alkyl Radical …
1 Sept 2015 in Fk
Public funding (€398,969): EPC-based carrier systems for the specific transport of CNS therapeutics via the blood-brain barrier (EPC-BBB) - sub-projects: Determination of physicochemical and galenic …
31 Jul 2015
Officer (2)
3 Jun 2015
Officer (1)
15 May 2015
Annual report for the year ending 31/12/2014 · Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014
19 Mar 2015
No longer Officer (1)
12 Jan 2015
Annual report for the year ending 31/12/2013 · Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013 · Shareholding: 100% der Anteile an der AbbVie Komplementär GmbH, die Komplementärin …
Year 2014 in Epobase
21 European patent filings: Oxindole Derivatives Carrying a Piperidyl-Substituted Azetidinyl Substituent and USE Thereof for Treating Vasopressine-Related Diseases …
7 Nov 2014
No longer Officer (3) · Officer (1)
Year 2014 in Dp
10 patent filings: Acylaminocycloalkyl compounds for the treatment of diseases that respond to the modulation of the dopamine D3 receptor …
15 May 2014
Officer (1)
9 Apr 2014
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012 · Earnings statement for 31/12/2012 · Shareholding: 100 % der Anteile an der AbbVie Komplementär GmbH
19 Feb 2014
Officer (1)
30 Jan 2014
Address
Year 2013 in Epobase
18 European patent filings: Substituted 2-Phenylbenzimidazoles and Their use as Parp Inhibitors …
Year 2013 in Dp
5 patent filings: Isoindolin Derivatives, Pharmaceutical Compositions With This and Your Therapeutic Use …
26 Jul 2013
Officer (1)
17 Jul 2013
Officer (1)
3 Jul 2013
No longer Officer (4) · Officer (2)
25 Jun 2013
No longer Officer (4) · Officer (2)
21 Dec 2012
Officer (1)
Year 2012 in Epobase
8 European patent filings: Composition and Method for the Diagnosis and Treatment of Iron-Related Disorders …
23 Nov 2012
Address
7 Nov 2012
Officer (38)
7 Nov 2012
Address · Sub­sidiary: 67061 Ludwigshafen,;
2 Nov 2012 via Abbott GmbH & Co. KG
Acquisition, Break-up: Abbott GmbH & Co. KG
2 Nov 2012
Acquisition: Abbott GmbH & Co. KG · Break-up: Abbott GmbH & Co. KG
1 Oct 2012 in Fk
Public funding (€792,808): CI3: Identification of neuroprotective, neuroregenerative molecular markers for the treatment of multiple sclerosis-associated neurodegeneration
Year 2012 in Dp
5 patent filings: 1- (pyridine-2-yl) -3- (quinoline-4-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) inhibitors for the treatment of neurodegenerative diseases …
11 Jun 2012
Reg­is­tra­tion · General partner: AbbVie Komplementär GmbH · Address · Proxy · Corporate Purpose

Mentions

7 Jun 2023
Direct parent: Abbvie Inc
7 Jun 2023
Ultimate parent: Abbvie Inc

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close